FR2686087B1 - - Google Patents

Info

Publication number
FR2686087B1
FR2686087B1 FR9200255A FR9200255A FR2686087B1 FR 2686087 B1 FR2686087 B1 FR 2686087B1 FR 9200255 A FR9200255 A FR 9200255A FR 9200255 A FR9200255 A FR 9200255A FR 2686087 B1 FR2686087 B1 FR 2686087B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9200255A
Other languages
French (fr)
Other versions
FR2686087A1 (fr
Inventor
Boumsell
Bensussan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR9200255A priority Critical patent/FR2686087A1/fr
Priority to PCT/FR1993/000025 priority patent/WO1993014125A1/fr
Publication of FR2686087A1 publication Critical patent/FR2686087A1/fr
Application granted granted Critical
Publication of FR2686087B1 publication Critical patent/FR2686087B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9200255A 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. Granted FR2686087A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
PCT/FR1993/000025 WO1993014125A1 (fr) 1992-01-13 1993-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Publications (2)

Publication Number Publication Date
FR2686087A1 FR2686087A1 (fr) 1993-07-16
FR2686087B1 true FR2686087B1 (esLanguage) 1994-04-22

Family

ID=9425559

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9200255A Granted FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Country Status (2)

Country Link
FR (1) FR2686087A1 (esLanguage)
WO (1) WO1993014125A1 (esLanguage)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
WO2009067660A2 (en) 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
PT2427212T (pt) 2009-05-08 2017-11-20 Vaccinex Inc Anticorpos anti-cd100 e métodos para utilização dos mesmos
US9963504B2 (en) 2010-09-02 2018-05-08 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
WO2013055922A1 (en) 2011-10-11 2013-04-18 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
BR112014010664A2 (pt) 2011-11-02 2017-04-25 Biogen Idec Int Neuroscience Gmbh uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
JP6611709B2 (ja) 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AU2016239331C1 (en) 2015-03-31 2020-01-30 Medimmune Limited A novel IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
EP3535293A1 (en) 2016-11-07 2019-09-11 Crossbeta Biosciences B.V. Novel amyloid beta oligomer specific binding molecule
DK3600419T5 (en) 2017-03-20 2024-05-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
EP3618865A4 (en) 2017-05-05 2021-05-05 Vaccinex, Inc. HUMAN ANTI-SEMAPHORINE 4D ANTIBODY
PL3672631T3 (pl) 2017-08-22 2023-06-26 Biogen Ma Inc. Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi
AU2020244862B2 (en) 2019-03-28 2023-01-05 Merck Kgaa Semaphorin-4D antagonists for use in cancer therapy
WO2020257640A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
WO2021021991A1 (en) 2019-08-01 2021-02-04 Vaccinex,Inc. Combined inhibition of semaphorin-4d and tgfb and compositions therefor
MX2022016188A (es) 2020-06-25 2023-10-30 Vaccinex Inc Uso de moléculas de unión a semaforina-4d para el tratamiento del síndrome de rett.
WO2023048726A1 (en) 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
WO2026030311A1 (en) 2024-07-29 2026-02-05 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules to treat cognitive impairment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942579A1 (de) * 1989-12-22 1991-06-27 Basf Ag Neue proteine

Also Published As

Publication number Publication date
FR2686087A1 (fr) 1993-07-16
WO1993014125A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
TW257728B (esLanguage)
FR2686087B1 (esLanguage)
DK0553875T3 (esLanguage)
FR2699136B1 (esLanguage)
TW230797B (esLanguage)
TW221038B (esLanguage)
DK0576346T3 (esLanguage)
DK0596750T3 (esLanguage)
DK0574087T3 (esLanguage)
DK0581129T3 (esLanguage)
DK0571874T3 (esLanguage)
TW221540B (esLanguage)
IN185630B (esLanguage)
TW222311B (esLanguage)
DK0576097T3 (esLanguage)
TW240311B (esLanguage)
TW237579B (esLanguage)
DK0590732T3 (esLanguage)
TW216450B (esLanguage)
TW225073B (esLanguage)
AU631518B2 (esLanguage)
TW235263B (esLanguage)
IN185207B (esLanguage)
IN179361B (esLanguage)
AU2619992A (esLanguage)

Legal Events

Date Code Title Description
ST Notification of lapse